Pairing data and research expertise to revolutionize the discovery, development and commercialization of life sciences innovations
Cerner Corporation today announced the acquisition of Kantar Health, a division of Kantar Group, for $375 million in cash, subject to adjustment. Kantar Health’s rich life sciences expertise will be combined with Cerner’s robust collection of real-world data (RWD) and technology and is expected to accelerate innovation in life sciences research and improve patient outcomes worldwide.
“The promise of real-world evidence to power drug discovery is right in front of us,” said Donald Trigg, president, Cerner. “Kantar Health is an important next step in building out the capabilities our growing network of provider clients need to fundamentally change the time and cost for clinical trials.”
The highly experienced teams at Kantar Health bring deep understanding of the needs of the pharmaceutical and life sciences industry. Their research and consulting solutions, complemented by Cerner’s RWD, position Cerner to help life sciences companies and research organizations with all aspects of the therapeutic lifecycle.
The growing Cerner Learning Health NetworkSM client consortium, which today represents 92 million patients and 776 million clinical encounters, will be able to engage more with life sciences companies for funded research studies. A stronger collaboration between providers and the pharmaceutical industry is enabled through this acquisition. It will help researchers generate more health insights and use differentiated RWD assets and expertise to address the most complex clinical research questions.
As a result of the transaction closing, the Kantar Health team located around the world is joining Cerner and will be integrated within its Strategic Growth business. This includes Kantar Health’s research and consulting solutions and global clients. Lynnette Cooke, head of Kantar Health, will continue to lead the team and join the Cerner leadership.
“Kantar Health and Cerner’s Strategic Growth business have a great deal in common, starting with a vision to advance patient care around the world. Culturally, we share the same values when it comes to how we develop our people, our offer and our client base. I’m excited to continue leading the team as we integrate with Cerner,” said Cooke. “I have great admiration for Cerner’s health technologies and am inspired by their strategic vision for future growth. Our collective capabilities and assets will enable the acceleration of innovation and elevate our expertise in addressing the most complex clinical research questions changing the way healthcare is developed and delivered.”
All statements in this press release that do not directly and exclusively relate to historical facts constitute forward-looking statements. These forward-looking statements are based on the current beliefs, expectations and assumptions of Cerner’s management with respect to future events and are subject to a number of significant risks and uncertainties. It is important to note that Cerner’s performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. The words “expected” and “position”, or the negative of these words, variations thereof or similar expressions are intended to identify such forward-looking statements. For example, our forward-looking statements include statements regarding the future benefits or synergies of the transaction. Factors that could cause or contribute to such differences include, but are not limited to: risks inherent with business acquisitions and integrations, such as difficulties and operational and financial risks associated with integrating Cerner and the acquired business generally and during the COVID-19 pandemic; the occurrence of any event, change or other circumstances that could make closing in a specific country impracticable; risks related to disruption of management time from ongoing business operations due to the transaction and integration; failure to realize the synergies, market opportunities and other benefits expected from the transaction; risk that the assets and business acquired may not continue to be commercially successful; the ability of Cerner and Kantar Health to retain customers and key personnel and to maintain relationships with key suppliers of the acquired business; unexpected costs, charges or expenses resulting from the transaction or the integration; litigation or claims relating to the transaction or the acquired assets and business; and the extent to which the COVID-19 pandemic and measures taken in response thereto could adversely affect the business acquired and the assumptions management has used in its evaluation of the transaction. Additional discussion of these and other risks, uncertainties and factors affecting Cerner’s business is contained in Cerner’s filings with the Securities and Exchange Commission. The reader should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. Except as required by law, Cerner undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events, or changes in our business, results of operations or financial condition over time.